| Sep 25 |
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
|
| Sep 3 |
Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On
|
| Sep 3 |
Avadel Pharmaceuticals Announces Publication of RESTORE Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ™ Dosing (sodium oxybate) Extended-Release Oral Suspension (CIII)
|
| Aug 28 |
Avadel Pharma Shares Fall After Split Decision in Legal Fight Over Narcolepsy Drug
|
| Aug 28 |
Avadel says court denies Jazz Pharma request on lumryz in narcolepsy (update)
|
| Aug 28 |
Avadel Pharmaceuticals plc (AVDL): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
|
| Aug 20 |
Avadel Pharmaceuticals Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension
|
| Aug 9 |
Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript
|
| Aug 9 |
Avadel Pharmaceuticals reports Q2 results
|
| Aug 8 |
Avadel Pharmaceuticals plc 2024 Q2 - Results - Earnings Call Presentation
|
